BAYZF - Bayer pulling lymphoma drug from US market over failed study
2023-11-13 17:03:00 ET
More on Bayer
- Breaking Up Bayer? Probably Not!
- Bayer Aktiengesellschaft 2023 Q3 - Results - Earnings Call Presentation
- Bayer Aktiengesellschaft (BAYZF) Q3 2023 Earnings Call Transcript
- Bayer considering breakup but not immediate three-way split, CEO Anderson says
- Bayer slapped with $332M jury verdict in Roundup cancer trial
For further details see:
Bayer pulling lymphoma drug from US market over failed study